LAURAN NEERGAARD and MIKE STOBBE Associated Press
U.S. health advisers on Friday urged resuming COVID-19 vaccinations with Johnson & Johnson’s single-dose shot, saying its benefits outweigh a rare risk of blood clots in line with Europe’s rollout.
Federal health officials uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.
Advisers to the Centers for Disease Control and Prevention said while J&J’s vaccine is important for fighting the pandemic, it’s also critical that younger women be told about that risk in clear, understandable terms so they can decide if they’d rather choose an alternate vaccine instead.
US Ends Pause On Johnson & Johnson Vaccine, Says More Benefits Than Risks ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
U.S. to resume J&J COVID vaccinations despite rare clot risk FILE - In this March 3, 2021, file photo, U.S. Army medic Kristen Rogers, of Waxhaw, N.C., holds a vial of the Johnson & Johnson COVID-19 vaccine in North Miami, Fla. With the U.S. pause of the vaccine, authorities are weighing whether to resume the shots the way European regulators decided to with warnings of a very rare risk. New guidance is expected late Friday, April 23, after a government advisory panel deliberates a link between the shot and a handful of vaccine recipients who developed highly unusual blood clots.
US to resume use of Johnson & Johnson Covid vaccine
Updated Apr 23, 2021;
Posted Apr 23, 2021
U.S. Army medic Kristen Rogers of Waxhaw, North Carolina holds a vial of the Johnson & Johnson Covid-19 vaccine in North Miami, Florida in March.Marta Lavandier | AP Photo
Facebook Share
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson’s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.
The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.